Curium to acquire Lantheus in all-cash deal worth up to $8bn

CapVest Partners-backed Curium has agreed to bargain rival US-based radiopharmaceutical institution Lantheus successful an all-cash woody worthy up to astir $8bn.

The woody volition instrumentality the Nasdaq-listed Lantheus private.

Under the agreement, Curium US volition acquisition each outstanding shares of Lantheus for $102.50 per stock upon closing.

Lantheus' shareholders are besides acceptable to person non-transferable contingent worth rights (CVRs) that could supply up to an further $12.00 per stock if definite commercialized milestones for the company's merchandise portfolio are met by 2030. This brings the imaginable full information per stock to $114.50.

The connection represents a 38% premium to Lantheus' 60-day volume-weighted mean price, a 29% premium to its 30-day average. It is besides 21% supra the company's closing terms arsenic of 21 May 2026, the past time earlier media reports emerged astir the imaginable sale.

The projected transaction has received unanimous support from Lantheus' Board of Directors.

Lantheus enforcement seat and CEO Mary Anne Heino said: "We judge this transaction is the eventual validation of what the Lantheus squad has built implicit 7 decades of innovation successful radiopharmaceuticals.

"Combining strategically with Curium brings unneurotic 2 pioneers with complementary strengths and a shared passionateness for atomic medicine. Together, we tin broaden and accelerate diligent entree to life-changing diagnostics and therapeutics and afloat realise the differentiated outcomes and worth radiopharmaceuticals tin deliver."

If approved and finalised, the caller combined entity would run crossed oncology, neurology, and cardiology successful much than 70 countries. It volition integrate Curium's theranostics capabilities and planetary manufacturing operations with Lantheus' US-based radiodiagnostics business.

Curium CEO Renaud Dehareng said: "Lantheus is the perfect spouse to accelerate what we person been gathering astatine Curium. We person executed a strategy to physique an innovative, theragnostic level by expanding our planetary manufacturing footprint, advancing our radioligand therapy pipeline crossed cardinal regions, and positioning Curium to thrust the adjacent procreation of theragnostic innovation.

"Lantheus' complementary concern accelerates our strategy with a robust US commercialized infrastructure, a complementary F18-isotope based prostate diagnostics franchise and marks our introduction successful the US marketplace for diagnostic solutions targeting Neurology and Echocardiography.

"Together, we volition supply meaningful theragnostic options to patients from SPECT and PET diagnostics to targeted radioligand therapy crossed the globe. This operation unlocks an accidental that neither institution could execute alone, arsenic it positions america to scope importantly much patients and clinicians globally."